Effect of curcumin and paclitaxel on breast carcinogenesis

Quispe-Soto,Edgar Teddy; Calaf,Gloria M.

doi:10.3892/ijo.2016.3741

Effect of curcumin and paclitaxel on breast carcinogenesis

Authors:
- Edgar Teddy Quispe-Soto
- Gloria M. Calaf
View Affiliations

Affiliations: Instituto de Alta Investigación, Universidad de Tarapacá, Arica 8097877, Chile
Published online on: October 19, 2016 https://doi.org/10.3892/ijo.2016.3741
Pages: 2569-2577

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Global cancer burden increased to 14.1 million new cases in 2012; and breast cancer is the most common cancer in women worldwide, with nearly 1.7 million new cases diagnosed in 2012. Curcumin is the major bioactive ingredient extracted from the rhizome of the plant Curcuma longa (turmeric). Paclitaxel is a microtubule-stabilizing agent originally isolated from the bark of Taxus brevifolia. Curcumin and paclitaxel were evaluated with two human breast cancer cell lines as the luminal MCF-7 and the basal-like MDA-MB-231 that are either positive or negative for hormonal receptors estrogen receptor, progesterone receptor and HER2, respectively. Results indicated that curcumin combined with paclitaxel decreased c-Ha-Ras, Rho-A, p53 and Bcl-xL gene expression in comparison to control and substances alone in MCF-7 cell line. These two substances alone and combined decreased gene expression of Bcl-2 and NF-κB. However, CCND1 increased when both substances were combined in MCF-7 cells. Such substances decreased Bcl-2 and increased Bax protein expression. However, curcumin alone decreased IκBα and Stat-3 gene expression. Paclitaxel alone and combined increased IκBα and Stat-3. Curcumin alone and combined with paclitaxel increased p53, Bid, caspase-3, caspase-8 and Bax gene expression in MDA-MB-231, whereas Bcl-xL decreased such expression in MDA-MB-231 cells. When paclitaxel and curcumin were combined the expression of Bcl-2 protein was decreased. However, either substance alone and combined increased Bax protein expression corroborating the apoptotic effect of these substances. It can be concluded that curcumin may be of considerable value in synergistic therapy of breast cancer reducing the associated toxicity with use of drugs.

View Figures

View References

1	Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D and Bray F: Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer. 49:1374–1403. 2013. View Article : Google Scholar : PubMed/NCBI
2	Calaf GM, Echiburú-Chau C, Roy D, Chai Y, Wen G and Balajee AS: Protective role of curcumin in oxidative stress of breast cells. Oncol Rep. 26:1029–1035. 2011.PubMed/NCBI
3	Calaf GM, Echiburú-Chau C, Wen G, Balajee AS and Roy D: Effect of curcumin on irradiated and estrogen-transformed human breast cell lines. Int J Oncol. 40:436–442. 2012.
4	Joe B, Vijaykumar M and Lokesh BR: Biological properties of curcumin-cellular and molecular mechanisms of action. Crit Rev Food Sci Nutr. 44:97–111. 2004. View Article : Google Scholar : PubMed/NCBI
5	Gabizon A, Price DC, Huberty J, Bresalier RS and Papahadjopoulos D: Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: Biodistribution and imaging studies. Cancer Res. 50:6371–6378. 1990.PubMed/NCBI
6	Fu Y, Li S, Zu Y, Yang G, Yang Z, Luo M, Jiang S, Wink M and Efferth T: Medicinal chemistry of paclitaxel and its analogues. Curr Med Chem. 16:3966–3985. 2009. View Article : Google Scholar : PubMed/NCBI
7	Okano J and Rustgi AK: Paclitaxel induces prolonged activation of the Ras/MEK/ERK pathway independently of activating the programmed cell death machinery. J Biol Chem. 276:19555–19564. 2001. View Article : Google Scholar : PubMed/NCBI
8	McGrogan BT, Gilmartin B, Carney DN and McCann A: Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta. 1785:96–132. 2008.
9	Jin C, Wu H, Liu J, Bai L and Guo G: The effect of paclitaxel-loaded nanoparticles with radiation on hypoxic MCF-7 cells. J Clin Pharm Ther. 32:41–47. 2007. View Article : Google Scholar : PubMed/NCBI
10	Barbacid M: ras genes. Annu Rev Biochem. 56:779–827. 1987. View Article : Google Scholar : PubMed/NCBI
11	Kasid A, Lippman ME, Papageorge AG, Lowy DR and Gelmann EP: Transfection of v-rasH DNA into MCF-7 human breast cancer cells bypasses dependence on estrogen for tumorigenicity. Science. 228:725–728. 1985. View Article : Google Scholar : PubMed/NCBI
12	Yu LLG and Gu JY: Advances in the role of Rho sub-family in tumor invasion. Fudan Univ J Med Sci. 37:617–619. 2010.
13	Hall A: Rho GTPases and the actin cytoskeleton. Science. 279:509–514. 1998. View Article : Google Scholar : PubMed/NCBI
14	DerMardirossian C and Bokoch GM: GDIs: Central regulatory molecules in Rho GTPase activation. Trends Cell Biol. 15:356–363. 2005. View Article : Google Scholar : PubMed/NCBI
15	Olofsson B: Rho guanine dissociation inhibitors: Pivotal molecules in cellular signalling. Cell Signal. 11:545–554. 1999. View Article : Google Scholar : PubMed/NCBI
16	Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, Hoffman RM and Lowe SW: A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell. 109:335–346. 2002. View Article : Google Scholar : PubMed/NCBI
17	Vogelstein B, Lane D and Levine AJ: Surfing the p53 network. Nature. 408:307–310. 2000. View Article : Google Scholar : PubMed/NCBI
18	Hengartner MO: The biochemistry of apoptosis. Nature. 407:770–776. 2000. View Article : Google Scholar : PubMed/NCBI
19	Yonish-Rouach E, Grunwald D, Wilder S, Kimchi A, May E, Lawrence JJ, May P and Oren M: p53-mediated cell death: Relationship to cell cycle control. Mol Cell Biol. 13:1415–1423. 1993. View Article : Google Scholar : PubMed/NCBI
20	Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B and Reed JC: Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 9:1799–1805. 1994.PubMed/NCBI
21	Miyashita T and Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 80:293–299. 1995. View Article : Google Scholar : PubMed/NCBI
22	Cory S and Adams JM: The Bcl2 family: Regulators of the cellular life-or-death switch. Nat Rev Cancer. 2:647–656. 2002. View Article : Google Scholar : PubMed/NCBI
23	García-Sáez AJ: The secrets of the Bcl-2 family. Cell Death Differ. 19:1733–1740. 2012. View Article : Google Scholar : PubMed/NCBI
24	González de Aguilar JL, Gordon JW, René F, de Tapia M, Lutz-Bucher B, Gaiddon C and Loeffler JP: Alteration of the Bcl-x/Bax ratio in a transgenic mouse model of amyotrophic lateral sclerosis: Evidence for the implication of the p53 signaling pathway. Neurobiol Dis. 7:406–415. 2000. View Article : Google Scholar : PubMed/NCBI
25	van Delft MF and Huang DC: How the Bcl-2 family of proteins interact to regulate apoptosis. Cell Res. 16:203–213. 2006. View Article : Google Scholar : PubMed/NCBI
26	Jürgensmeier JM, Xie Z, Deveraux Q, Ellerby L, Bredesen D and Reed JC: Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci USA. 95:4997–5002. 1998. View Article : Google Scholar : PubMed/NCBI
27	Placzek WJ, Wei J, Kitada S, Zhai D, Reed JC and Pellecchia M: A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy. Cell Death Dis. 1:e402010. View Article : Google Scholar
28	Davids MS and Letai A: Targeting the B-cell lymphoma/leukemia 2 family in cancer. J Clin Oncol. 30:3127–3135. 2012. View Article : Google Scholar : PubMed/NCBI
29	Walensky LD: From mitochondrial biology to magic bullet: Navitoclax disarms BCL-2 in chronic lymphocytic leukemia. J Clin Oncol. 30:554–557. 2012. View Article : Google Scholar
30	Dai Y, Lawrence TS and Xu L: Overcoming cancer therapy resistance by targeting inhibitors of apoptosis proteins and nuclear factor-kappa B. Am J Transl Res. 1:1–15. 2009.PubMed/NCBI
31	Han J, Sun M, Cui Y, Wang T, Zhang W, Guo M, Zhou Y, Liu W, Zhang M, Duan J, et al: Kushen flavonoids induce apoptosis in tumor cells by inhibition of NF-kappaB activation and multiple receptor tyrosine kinase activities. Phytother Res. 21:262–268. 2007. View Article : Google Scholar
32	Wulczyn FG, Naumann M and Scheidereit C: Candidate proto-oncogene bcl-3 encodes a subunit-specific inhibitor of transcription factor NF-kappa B. Nature. 358:597–599. 1992. View Article : Google Scholar : PubMed/NCBI
33	Bours V, Franzoso G, Azarenko V, Park S, Kanno T, Brown K and Siebenlist U: The oncoprotein Bcl-3 directly transactivates through kappa B motifs via association with DNA-binding p50B homodimers. Cell. 72:729–739. 1993. View Article : Google Scholar : PubMed/NCBI
34	Dobrzanski P, Ryseck RP and Bravo R: Differential interactions of Rel-NF-kappa B complexes with I kappa B alpha determine pools of constitutive and inducible NF-kappa B activity. EMBO J. 13:4608–4616. 1994.PubMed/NCBI
35	Baldwin AS Jr: The NF-kappa B and I kappa B proteins: New discoveries and insights. Annu Rev Immunol. 14:649–683. 1996. View Article : Google Scholar : PubMed/NCBI
36	Cheng JD, Ryseck RP, Attar RM, Dambach D and Bravo R: Functional redundancy of the nuclear factor kappa B inhibitors I kappa B alpha and I kappa B beta. J Exp Med. 188:1055–1062. 1998. View Article : Google Scholar : PubMed/NCBI
37	Huxford T, Huang DB, Malek S and Ghosh G: The crystal structure of the IkappaBalpha/NF-kappaB complex reveals mechanisms of NF-kappaB inactivation. Cell. 95:759–770. 1998. View Article : Google Scholar : PubMed/NCBI
38	Tam WF and Sen R: IkappaB family members function by different mechanisms. J Biol Chem. 276:7701–7704. 2001. View Article : Google Scholar : PubMed/NCBI
39	Hoffmann A, Levchenko A, Scott ML and Baltimore D: The IkappaB-NF-kappaB signaling module: Temporal control and selective gene activation. Science. 298:1241–1245. 2002. View Article : Google Scholar : PubMed/NCBI
40	Anest V, Hanson JL, Cogswell PC, Steinbrecher KA, Strahl BD and Baldwin AS: A nucleosomal function for IkappaB kinase-alpha in NF-kappaB-dependent gene expression. Nature. 423:659–663. 2003. View Article : Google Scholar : PubMed/NCBI
41	Calaf G and Russo J: Transformation of human breast epithelial cells by chemical carcinogens. Carcinogenesis. 14:483–492. 1993. View Article : Google Scholar : PubMed/NCBI
42	Zhan Y, Chen Y, Liu R, Zhang H and Zhang Y: Potentiation of paclitaxel activity by curcumin in human breast cancer cell by modulating apoptosis and inhibiting EGFR signaling. Arch Pharm Res. 37:1086–1095. 2014. View Article : Google Scholar
43	Aggarwal BB, Shishodia S, Takada Y, Banerjee S, Newman RA, Bueso-Ramos CE and Price JE: Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res. 11:7490–7498. 2005. View Article : Google Scholar : PubMed/NCBI
44	Kang HJ, Lee SH, Price JE and Kim LS: Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB in breast cancer cells and potentiates the growth inhibitory effect of paclitaxel in a breast cancer nude mice model. Breast J. 15:223–229. 2009. View Article : Google Scholar : PubMed/NCBI
45	Choudhuri T, Pal S, Agwarwal ML, Das T and Sa G: Curcumin induces apoptosis in human breast cancer cells through p53-dependent Bax induction. FEBS Lett. 512:334–340. 2002. View Article : Google Scholar : PubMed/NCBI
46	Masuelli L, Benvenuto M, Fantini M, Marzocchella L, Sacchetti P, Di Stefano E, Tresoldi I, Izzi V, Bernardini R, Palumbo C, et al: Curcumin induces apoptosis in breast cancer cell lines and delays the growth of mammary tumors in neu transgenic mice. J Biol Regul Homeost Agents. 27:105–119. 2013.PubMed/NCBI
47	Siddiqui RA, Harvey KA, Walker C, Altenburg J, Xu Z, Terry C, Camarillo I, Jones-Hall Y and Mariash C: Characterization of synergistic anti-cancer effects of docosahexaenoic acid and curcumin on DMBA-induced mammary tumorigenesis in mice. BMC Cancer. 13:4182013. View Article : Google Scholar : PubMed/NCBI
48	Lu WD, Qin Y, Yang C, Li L and Fu ZX: Effect of curcumin on human colon cancer multidrug resistance in vitro and in vivo. Clinics (Sao Paulo). 68:694–701. 2013. View Article : Google Scholar
49	Thiyagarajan S, Thirumalai K, Nirmala S, Biswas J and Krishnakumar S: Effect of curcumin on lung resistance-related protein (LRP) in retinoblastoma cells. Curr Eye Res. 34:845–851. 2009. View Article : Google Scholar : PubMed/NCBI
50	Gallardo M and Calaf GM: Curcumin and epithelial-mesenchymal transition in breast cancer cells transformed by low doses of radiation and estrogen. Int J Oncol. 48:2534–2542. 2016.PubMed/NCBI
51	Gallardo M and Calaf GM: Curcumin inhibits invasive capabilities through epithelial mesenchymal transition in breast cancer cell lines. Int J Oncol. 49:1019–1027. 2016.PubMed/NCBI